Alcon Wins FDA Approval for OTC Brytly Eye Drops
ALC is trading near its 52-week low of $61.835 (7.2% above the low).
Summary
Alcon secured approval to sell Brytly eye drops over the counter, opening the product to the retail channel without a prescription. The OTC switch expands the addressable market beyond prescription-only buyers and adds a consumer-facing revenue stream to Alcon's vision care franchise. This follows a strong Q2 in which sales rose 8% to $2.8 billion and management raised full-year core margin and EPS guidance, so the approval extends an already improving product story. Bausch + Lomb (BLCO) competes directly in the same eye-care space and faces a modest competitive headwind from Alcon's broader OTC reach. No financial terms or launch timing were disclosed.
At the time of this announcement, ALC was trading at $66.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $33.1B. The 52-week trading range was $61.84 to $87.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.